Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Managment's guidance too conversative, more upside

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Great Wall is poised for a material leap in earnings on the back of new product launches in the SUV&nbsp;segment. This is the only major revenue and profit growth driver for the company now with more&nbsp;than 70% of the volumes SUV's. We believe that this trend of more revenues from SUV's will&nbsp;continue into this year as well driving earnings beats over the street.In this insight, we present detailed data and illustrations to back our argument.&nbsp;

Great Wall is poised for a material leap in earnings on the back of new product launches in the SUV&nbsp;segment. This is the only major revenue and profit growth driver for the company now with more&nbsp;than 70% of the volumes SUV's. We believe that this trend of more revenues from SUV's will&nbsp;continue into this year as well driving earnings beats over the street.In this insight, we present detailed data and illustrations to back our argument.&nbsp;

Great Wall Motors:  overly conservative forecasts; structural uplift from SUVs ahead